Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026 is attached herewith
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gufic Biosciences reported standalone FY26 revenue of ₹94,047.54 Lakhs, up 14.7% YoY from ₹81,980.59 Lakhs. However, net profit declined 9.7% to ₹6,314.87 Lakhs from ₹6,993.28 Lakhs, impacted by higher raw material costs and finance costs. Q4 FY26 showed strong recovery with net profit of ₹2,057.44 Lakhs vs ₹797.41 Lakhs in Q4 FY25. Consolidated PAT stood at ₹6,421.27 Lakhs. Total assets increased to ₹1,34,158.84 Lakhs from ₹1,16,962.63 Lakhs. The company declared a dividend of ₹0.10 per share (10%). Working capital consumption was significant with inventory increasing by ₹10,759.76 Lakhs. Auditors issued an unmodified opinion.
Revenue growth of ~15% is positive but the PAT decline of ~10% is concerning, likely impacting near-term stock sentiment. The large inventory buildup signals working capital pressure despite improved quarterly performance.